Search

Your search keyword '"GREGGI, S."' showing total 406 results
Start Over Author "GREGGI, S."
406 results on '"GREGGI, S."'

102. Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological cancer Cooperative Group study

Author

Vermorken, Jan Baptist, Landoni, F, Pecorelli, Sërgio, Piccart-Gebhart, Martine, van der Burg, Maria, ten Bokkel Huinink, Wim, George, Martine, Greggi, S, Rotmensz, N, Vermorken, Jan Baptist, Landoni, F, Pecorelli, Sërgio, Piccart-Gebhart, Martine, van der Burg, Maria, ten Bokkel Huinink, Wim, George, Martine, Greggi, S, and Rotmensz, N

Abstract

info:eu-repo/semantics/published

Published
1991

114. Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer

Author

Menichella, G., primary, Pierelli, L., additional, Foddai, M. L., additional, Paoloni, A., additional, Vittori, M., additional, Serafini, R., additional, Panici, P. Benedetti, additional, Scambia, G., additional, Baiocchi, G., additional, Greggi, S., additional, Laurelli, G., additional, Salerno, G., additional, Mancuso, S., additional, Mango, G., additional, and Bizzi, B., additional

Published
1991
Full Text
View/download PDF

123. Circulating Tumor Markers in Cervical Cancer.

Author

Benedetti Panici, P., Scambia, G., Baiocchi, G., Sonsini, C., Greggi, S., Battaglia, F., and Mancuso, S.

Abstract

Serum levels of CA 19-9, CA 125 and CA 15-3 were measured in 91 patients with cervical cancer (16 with intraepithelial neoplasia and 75 with invasive cancer). In 35 patients with locally advanced cervical cancer, serum marker levels were measured at monthly intervals during neo-adjuvant chemotherapy. CA 19-9 was found to be abnormally high only in advanced stages with an overall sensitivity of 7.3%. CA 125 and CA 15-3 were elevated in 31.9 and 23.1 % of the patients, respectively, with a combined sensitivity of about 40%. The mean values of CA 125 and CA 15-3 were positively related to clinical stage and tumor differentiation. CA 125 and CA 15-3 values were correlated with response to chemotherapy in more than 80% of the cases. These findings suggest that CA 125 and CA 15-3 could be usefully employed in the management of cervical cancer. Copyright © 1989 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
1989
Full Text
View/download PDF

124. Modified type IV-V radical hysterectomy with systematic pelvic and aortic lymphadenectomy in the treatment of patients with stage III cervical carcinoma. Feasibility, technique, and clinical results.

Author

Benedetti-Panici, Pierluigi, Maneschi, Francesco, Cutillo, Giuseppe, Greggi, Stefano, Salerno, Maria Giovanna, Amoroso, Mariangela, Scambia, Giovanni, Mancuso, Salvatore, Benedetti-Panici, P, Maneschi, F, Cutillo, G, Greggi, S, Salerno, M G, Amoroso, M, Scambia, G, and Mancuso, S

Published
1996
Full Text
View/download PDF

125. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival.

Author

Panici, Pierluigi Benedetti, Scambia, Giovanni, Baiocchi, Gabriela, Greggi, Stefano, Ragusa, Guglielmo, Gallo, Angelo, Conte, Massimo, Battaglia, Francesco, Laurelli, Giuseppe, Rabitti, Carla, Capelli, Arnaldo, Mancuso, Salvatore, Panici, P B, Scambia, G, Baiocchi, G, Greggi, S, Ragusa, G, Gallo, A, Conte, M, and Battaglia, F

Published
1991
Full Text
View/download PDF

130. High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer

Author

Califano, D., Pignata, S., Losito, N. S., Ottaiano, A., Greggi, S., Simone, V., Cecere, S., Aiello, C., Esposito, F., Alfredo Fusco, Chiappetta, G., Califano, D., Pignata, S., Losito, N. S., Ottaiano, A., Greggi, S., DE SIMONE, V., Cecere, S., Aiello, C., Esposito, F., Fusco, Alfredo, and Gennaro, G.

Subjects
hmga2
Abstract

HMGA2 is a small, non-histone, chromatin-associated protein with a key role in tumorigenesis and adipogenesis. Indeed, HMGA2 overexpression has been frequently detected in several malignant neoplasms and inhibition of its expression prevents thyroid cell transformation. Moreover, HMGA2 null mice show a pigmy phenotype with a great reduction in fat tissue. To investigate whether HMGA2 expression correlates with clinico-pathological parameters and patient outcome, immunohistochemical analysis of HMGA2 expression was performed in ovarian cancer specimens from 117 patients. HMGA2 overexpression was found in 39% of the cases and, interestingly, positively correlated with the Body Mass Index (BMI). Moreover, high BMI (>=25 kg/m2 ) and high HMGA2 expression/BMI combined evaluation predicted shorter disease free survival. High BMI (>=25 kg/m2 ), high expression of HMGA2 and high HMGA2 expression/BMI combined evaluation predicted shorter overall survival. In multivariate analysis, the concomitant high expression of HMGA2 and high BMI (>=25 kg/m2 ) was an independent prognostic factor. Finally, the Body Mass Index (>=25 kg/m2 ) negatively correlated with the patient response to chemotherapy (P = 0.039). Therefore, the data reported herein suggest that the combined evaluation of HMGA2 expression and obesity assessed through BMI, can be considered a marker of poor prognosis in patients affected by ovarian carcinoma. J. Cell. Physiol. © 2013 Wiley Periodicals, Inc.

144. Authors' reply

Author

Panici, P. Benedetti, primary, Scambia, G., additional, Greggi, S., additional, Di Roberto, P., additional, Baiocchi, G., additional, and Mancuso, S., additional

Published
1989
Full Text
View/download PDF

145. The newly established familial ovarian cancer (FOC) European registry: preliminary results

Author

Greggi, S., Panici, P. Benedietti, Cento, R., Scambia, G., Genuardi, M., Chiara, S., DePalo, G., Favalli, G., Fiorentino, M., Fotiou, S., Hoff, A.M., Kaufmann, M., Melpignano, M., and Mancuso, S.

Subjects
Registries (in medicine) -- Management, Ovarian cancer, Health, Science and technology
Abstract

AUTHORS: S. Greggi, P. Benedietti Panici, R. Cento, G. Scambia, M. Genuardi, S. Chiara, G. DePalo, G. Favalli, M. Fiorentino, S. Fotiou, A.M. Hoff, M. Kaufmann, M. Melpignano and S. [...]

Published
1992

148. Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial

Author

Francesco Perrone, Ugo De Giorgi, Maria Carmela Piccirillo, Annamaria Ferrero, Andrea Lissoni, Mariateresa Lapresa, Laura Arenare, Giorgio Bogani, Nicoletta Colombo, Daniela Califano, Angiolo Gadducci, Enrico Breda, Raimondo Di Liello, Giovanni Scambia, Andrea De Censi, Gennaro Daniele, Piera Gargiulo, Sandro Pignata, Paolo Scollo, Ciro Gallo, Margherita Nardin, Saverio Cinieri, Rossella Lauria, Francesco Raspagliesi, Vanda Salutari, Simona Frezzini, Carmela Pisano, Stefano Greggi, Domenica Lorusso, G. Artioli, Mariagrazia Distefano, Sabrina Chiara Cecere, Dionyssios Katsaros, Germana Tognon, Clorinda Schettino, Di Liello, R, Arenare, L, Raspagliesi, F, Scambia, G, Pisano, C, Colombo, N, Frezzini, S, Tognon, G, Artioli, G, Gadducci, A, Lauria, R, Ferrero, A, Cinieri, S, De Censi, A, Breda, E, Scollo, P, De Giorgi, U, Lissoni, A, Katsaros, D, Lorusso, D, Salutari, V, Cecere, S, Lapresa, M, Nardin, M, Bogani, G, Distefano, M, Greggi, S, Gargiulo, P, Schettino, C, Gallo, C, Daniele, G, Califano, D, Perrone, F, Pignata, S, Piccirillo, M, Di Liello, R., Arenare, L., Raspagliesi, F., Scambia, G., Pisano, C., Colombo, N., Frezzini, S., Tognon, G., Artioli, G., Gadducci, A., Lauria, R., Ferrero, A., Cinieri, S., De Censi, A., Breda, E., Scollo, P., De Giorgi, U., Lissoni, A. A., Katsaros, D., Lorusso, D., Salutari, V., Cecere, S. C., Lapresa, M., Nardin, M., Bogani, G., Distefano, M., Greggi, S., Gargiulo, P., Schettino, C., Gallo, C., Daniele, G., Califano, D., Perrone, F., Pignata, S., and Piccirillo, M. C.

Subjects
medicine.medical_specialty, Bevacizumab, medicine.drug_class, medicine.medical_treatment, venous thromboembolism, ovarian cancer, Carcinoma, Ovarian Epithelial, Antineoplastic Agents, Immunological, Fibrinolytic Agents, Secondary analysis, Internal medicine, Thromboembolism, Antithrombotic, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Cumulative incidence, Aged, Ovarian Neoplasms, Chemotherapy, business.industry, Incidence (epidemiology), Anticoagulant, Obstetrics and Gynecology, Middle Aged, medicine.disease, Oncology, Female, Ovarian cancer, business, medicine.drug
Abstract

IntroductionThe use of routine antithrombotic prophylaxis is not recommended for advanced cancer patients receiving chemotherapy. The effect of bevacizumab-containing therapy on the risk of thromboembolic events remains controversial in ovarian cancer patients. We report on the incidence of thromboembolic events and the prevalence of antithrombotic therapy in patients enrolled in the single arm, phase IV, MITO-16A/MaNGO-OV2A trial.MethodsIn this trial, potential prognostic factors for patients with previously untreated ovarian cancer receiving a combination of platinum-based chemotherapy and bevacizumab were explored and the final analysis has already been reported. In this secondary analysis, the occurrence of thromboembolic events and the use of antithrombotic therapy were described according to the clinical characteristics of the patients. The prognostic role of thromboembolic events for progression-free and overall survival were also evaluated.ResultsFrom October 2012 to November 2014, 398 eligible patients were enrolled. 76 patients (19.1%) were receiving some type of anticoagulant or anti-aggregant treatment at baseline. Overall, 24 thromboembolic events were reported (cumulative incidence of 6.0%). The occurrence of thromboembolic events was not associated with baseline patient characteristics and was not modified by the use of antithrombotic prophylaxis (HR 0.60, 95% CI 0.18 to 2.0). Occurrence of thromboembolic events was not associated with progression-free survival (HR 1.34, 95% CI 0.83 to 2.15) or overall survival (HR 0.78, 95% CI 0.37 to 1.61).ConclusionsIn our study, a 6.0% rate of thromboembolic events was reported during treatment with bevacizumab plus chemotherapy. Thromboembolic events were not associated with the clinical characteristics of the patients or with the use of antithrombotic prophylaxis, nor did they significantly affect the long-term prognosis.Trial registration numberNCT01706120

Published
2021

149. High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes

Author

Giovanni Scambia, Mario Malzoni, Lavinia Mosca, Lorenzo Aguzzoli, Nicola Colacurci, Gabriele Carlinfante, Marco Petrillo, Stefano Greggi, Paolo Vercellini, Antonio Cianci, Francesco Raspagliesi, Andrea Giannini, Andrea Ciavattini, Viola Liberale, Sara Bosio, Luca Giannella, Maurizio Serati, Rocco Guerrisi, Simone Ferrero, Michele Desiato, Pierandrea De Iaco, Anna Myriam Perrone, Giorgio Bogani, Fabio Ghezzi, Biagio Contino, Francesca Falcone, Arsenio Spinillo, Francesco Sopracordevole, Claudia Brusadelli, Antonio Simone Laganà, Simona Ruisi, Maria Grazia Matarazzo, Pierluigi Benedetti Panici, Paola Carunchio, Giuseppe Sarpietro, Alessandro Ghelardi, Barbara Gardella, Francesco Plotti, Alice Bergamini, Margherita Fischetti, Antonino Ditto, Gian Franco Zannoni, Gabriella Ferrandina, Vincenzo Dario Mandato, Valentina Chiappa, Violante Di Donato, Raffaele Tinelli, Ermelinda Monti, Roberto Angioli, Salvatore Dessole, Annunziata Carlea, Ciro Pinelli, Fulvio Zullo, Salvatore Lopez, Sara Lovati, Tommaso Simoncini, Maria Giovanna Salerno, Mauro Signorelli, Rosa De Vincenzo, Cono Scaffa, Jvan Casarin, Chiara Borghi, Cristina Donfrancesco, Ludovico Muzii, Giovanni D'ippolito, Gaetano Valenti, Andrea Dell'Acqua, Giulia Dondi, Bogani, G., Sopracordevole, F., Di Donato, V., Ciavattini, A., Ghelardi, A., Lopez, S., Simoncini, T., Plotti, F., Casarin, J., Serati, M., Pinelli, C., Valenti, G., Bergamini, A., Gardella, B., Dell'Acqua, A., Monti, E., Vercellini, P., Fischetti, M., D'Ippolito, G., Aguzzoli, L., Mandato, V. D., Carunchio, P., Carlinfante, G., Giannella, L., Scaffa, C., Falcone, F., Borghi, C., Ditto, A., Malzoni, M., Giannini, A., Salerno, M. G., Liberale, V., Contino, B., Donfrancesco, C., Desiato, M., Perrone, A. M., Dondi, G., De Iaco, P., Chiappa, V., Ferrero, S., Sarpietro, G., Matarazzo, M. G., Cianci, A., Bosio, S., Ruisi, S., Guerrisi, R., Brusadelli, C., Mosca, L., Lagana', A. S., Tinelli, R., Signorelli, M., De Vincenzo, R., Zannoni, G. F., Ferrandina, G., Lovati, S., Petrillo, M., Dessole, S., Carlea, A., Zullo, F., Angioli, R., Greggi, S., Spinillo, A., Ghezzi, F., Colacurci, N., Muzii, L., Benedetti Panici, P., Scambia, G., Raspagliesi, F., Bogani G., Sopracordevole F., Di Donato V., Ciavattini A., Ghelardi A., Lopez S., Simoncini T., Plotti F., Casarin J., Serati M., Pinelli C., Valenti G., Bergamini A., Gardella B., Dell'acqua A., Monti E., Vercellini P., Fischetti M., D'ippolito G., Aguzzoli L., Mandato V.D., Carunchio P., Carlinfante G., Giannella L., Scaffa C., Falcone F., Borghi C., Ditto A., Malzoni M., Giannini A., Salerno M.G., Liberale V., Contino B., Donfrancesco C., Desiato M., Perrone A.M., Dondi G., De Iaco P., Chiappa V., Ferrero S., Sarpietro G., Matarazzo M.G., Cianci A., Bosio S., Ruisi S., Guerrisi R., Brusadelli C., Mosca L., Lagana' A.S., Tinelli R., Signorelli M., De Vincenzo R., Zannoni G.F., Ferrandina G., Lovati S., Petrillo M., Dessole S., Carlea A., Zullo F., Angioli R., Greggi S., Spinillo A., Ghezzi F., Colacurci N., Muzii L., Benedetti Panici P., Scambia G., and Raspagliesi F.

Subjects
0301 basic medicine, Adult, medicine.medical_specialty, HPV, Uterine Cervical Neoplasm, Prognosi, CIN, conization, negative, positive, Conization, Uterine Cervical Neoplasms, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Risk Factors, Retrospective Studie, medicine, Humans, Cervical Intraepithelial Neoplasia, Prospective cohort study, Propensity Score, Papillomavirus Infection, Retrospective Studies, Obstetrics, Proportional hazards model, business.industry, Risk Factor, Papillomavirus Infections, Obstetrics and Gynecology, Retrospective cohort study, Middle Aged, Prognosis, medicine.disease, Negative, Uterine Cervical Dysplasia, female genital diseases and pregnancy complications, 030104 developmental biology, Settore MED/40 - GINECOLOGIA E OSTETRICIA, Oncology, Dysplasia, 030220 oncology & carcinogenesis, Cohort, Propensity score matching, Population study, Female, business, Positive, Cohort study, Human
Abstract

Objective: To evaluate the outcomes of high-risk (HR) HPV-positive and -negative women affected by high-grade cervical dysplasia. Methods: This is a retrospective multi-institutional study. Medical records of consecutive patients with high-grade cervical dysplasia undergoing conization between 2010 and 2014 were retrieved. All patients included had at least 5 years of follow-up. A propensity-score matching was adopted in order to reduce the presence of confounding factors between groups. Kaplan-Meir and Cox hazard models were used to estimate 5-year outcomes. Results: Overall, data of 2966 women, affected by high-grade cervical dysplasia were reviewed. The study population included 1478 (85%) and 260 (15%) women affected by HR-HPV-positive and HR-HPV-negative high-grade cervical dysplasia. The prevalence of CIN2 and CIN3 among the HR-HPV-positive and -negative cohort was similar (p = 0.315). Patients with HR-HPV-positive high-grade cervical dysplasia were at higher risk of 5-year recurrence (after primary conization) that HR-HPV-negative patients (p < 0.001, log-rank test). Via multivariate analysis, HR-HPV-negative women were at low risk of recurrence (HR: 1.69 (95%CI: 1.05, 4.80); p = 0.018, Cox Hazard model). A propensity-score matched comparison was carried out in order to reduce biases that are related to the retrospective study design. In comparison to HR-HPV-negative patients, thosewith HR-HPV-positive CIN3 was associate with a 8-fold increase in the risk of recurrence (p < 0.001, log-rank test). Conclusions: HR-HPV-negative high-grade cervical dysplasia is not uncommon, accounting for 15% of our study population. Those patients experience more favorable outcomes than patients with documented HR-HPV infection(s). Further prospective studies are needed to corroborate our data.

Published
2021

150. Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison

Author

Mario Malzoni, Gaetano Valenti, Lavinia Mosca, Stefano Ferla, Nicola Colacurci, Paolo Vercellini, Antonio Cianci, Rocco Guerrisi, Claudia Brusadelli, Biagio Contino, Giovanni Scambia, Andrea Ciavattini, Umberto Leone Roberti Maggiore, Pierluigi Benedetti Panici, Gabriella Ferrandina, Stefano Greggi, Gabriele Carlifante, Giorgio Bogani, Barbara Gardella, Margherita Fischetti, Simone Ferrero, Maurizio Serati, Ciro Pinelli, Salvatore Lopez, Fulvio Zullo, Anna Myriam Perrone, Mauro Signorelli, Rosa De Vincenzo, Andrea Giannini, Raffaele Tinelli, Vincenzo Dario Mandato, Jvan Casarin, Arsenio Spinillo, Francesco Sopracordevole, Francesco Plotti, Violante Di Donato, Viola Liberale, Maria Grazia Matarazzo, Antonino Ditto, Annunziata Carlea, Ermelinda Monti, Lorenzo Aguzzoli, Maria Giovanna Salerno, Cono Scaffa, Francesca Falcone, Michele Desiato, Valentina Chiappa, Pierandrea De Iaco, Roberto Angioli, Alice Bergamini, Salvatore Dessole, Marco Petrillo, Simona Ruisi, Francesco Raspagliesi, Giulia Dondi, Fabio Ghezzi, Giovanni D'ippolito, Sara Bocio, Andrea Dell'Acqua, Giuseppe Sarpietro, Chiara Borghi, Alessandro Ghelardi, Paola Carunchio, Luca Gianella, Tommaso Simoncini, Cristina Donfrancesco, Ludovico Muzii, Gian Franco Zannoni, Bogani, G., Raspagliesi, F., Sopracordevole, F., Ciavattini, A., Ghelardi, A., Simoncini, T., Petrillo, M., Plotti, F., Lopez, S., Casarin, J., Serati, M., Pinelli, C., Valenti, G., Bergamini, A., Gardella, B., Dell'Acqua, A., Monti, E., Vercellini, P., D'Ippolito, G., Aguzzoli, L., Mandato, V. D., Carunchio, P., Carlifante, G., Giannella, L., Scaffa, C., Falcone, F., Ferla, S., Borghi, C., Ditto, A., Malzoni, M., Giannini, A., Salerno, M. G., Liberale, V., Contino, B., Donfrancesco, C., Desiato, M., Perrone, A. M., Dondi, G., De Iaco, P., Maggiore, U. L. R., Signorelli, M., Chiappa, V., Ferrero, S., Sarpietro, G., Matarazzo, M. G., Cianci, A., Bocio, S., Ruisi, S., Guerrisi, R., Brusadelli, C., Mosca, L., Tinelli, R., De Vincenzo, R., Zannoni, G. F., Ferrandina, G., Dessole, S., Angioli, R., Greggi, S., Spinillo, A., Ghezzi, F., Colacurci, N., Fischetti, M., Carlea, A., Zullo, F., Muzii, L., Scambia, G., Panici, P. B., Di Donato, V., Bogani G., Raspagliesi F., Sopracordevole F., Ciavattini A., Ghelardi A., Simoncini T., Petrillo M., Plotti F., Lopez S., Casarin J., Serati M., Pinelli C., Valenti G., Bergamini A., Gardella B., Dell'acqua A., Monti E., Vercellini P., D'ippolito G., Aguzzoli L., Mandato V.D., Carunchio P., Carlifante G., Giannella L., Scaffa C., Falcone F., Ferla S., Borghi C., Ditto A., Malzoni M., Giannini A., Salerno M.G., Liberale V., Contino B., Donfrancesco C., Desiato M., Perrone A.M., Dondi G., De Iaco P., Maggiore U.L.R., Signorelli M., Chiappa V., Ferrero S., Sarpietro G., Matarazzo M.G., Cianci A., Bocio S., Ruisi S., Guerrisi R., Brusadelli C., Mosca L., Tinelli R., De Vincenzo R., Zannoni G.F., Ferrandina G., Dessole S., Angioli R., Greggi S., Spinillo A., Ghezzi F., Colacurci N., Fischetti M., Carlea A., Zullo F., Muzii L., Scambia G., Panici P.B., and Di Donato V.

Subjects
medicine.medical_specialty, HPV, Cost effectiveness, Immunology, lcsh:Medicine, Lower risk, Article, 03 medical and health sciences, conization, 0302 clinical medicine, Primary prevention, Drug Discovery, medicine, Recurrent disease, LEEP, Pharmacology (medical), 030212 general & internal medicine, leep, vaccination, Pharmacology, Obstetrics, business.industry, lcsh:R, medicine.disease, Vaccination, Settore MED/40 - GINECOLOGIA E OSTETRICIA, Infectious Diseases, Loop electrosurgical excision procedure, Dysplasia, 030220 oncology & carcinogenesis, Propensity score matching, business
Abstract

Background: Primary prevention through vaccination is a prophylactic approach aiming to reduce the risk of developing human papillomavirus (HPV)-related lesions. No mature and long-term data supported the adoption of vaccination in women undergoing conization. Methods: This is a retrospective multi-institutional study. Charts of consecutive patients undergoing conization between 2010 and 2014 were collected. All patients included had at least 5 years of follow-up. We compared outcomes of patients undergoing conization plus vaccination and conization alone. A propensity-score matching algorithm was applied in order to reduce allocation biases. The risk of developing recurrence was estimated using Kaplan-Meir and Cox hazard models. Results: Overall, charts of 1914 women were analyzed. The study group included 116 (6.1%) and 1798 (93.9%) women undergoing conization plus vaccination and conization alone, respectively. Five-year recurrence rate was 1.7% (n = 2) and 5.7% (n = 102) after conization plus vaccination and conization alone, respectively (p = 0.068). After the application of a propensity-score matching, we selected 100 patients undergoing conization plus vaccination and 200 patients undergoing conization alone. The crude number of recurrences was 2 (2%) and 11 (5.5%) for patients undergoing conization plus vaccination and conization alone, respectively (p = 0.231). Vaccination had no impact on persistent lesions (no negative examination between conization and new cervical dysplasia, p = 0.603), but reduced the risk of recurrent disease (patients who had at least one negative examination between conization and the diagnosis of recurrent cervical dysplasia, p = 0.031). Conclusions: Patients having vaccination experience a slightly lower risk of recurrence than women who had not, although not statistically significantly different. Further evidence is needed to assess the cost effectiveness of adopting vaccination in this setting.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results